Clinical trials: Prostate Cancer Stage
Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
The study is being conducted to evaluate the efficacy and safety of SHR3680 plus androgen deprivation therapy (ADT) vs. placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer using pathologic…
- Trial name
- NCT05009290
- Testing
- SHR3680
- Where
- China
- Volunteers
- 391 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer
A Phase I/II study of an in-situ therapeutic cancer vaccine. Vaccines contain a source of antigen and and adjuvant. In this study the source of tumor antigen comes from the killing of a selected tumor by cryoablation (killing…
- Conditions
- Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT01065441
- Testing
- AlloStim, Cryoablation
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Michael Har-Noy
Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors
This is a first time in man (FTIM), Phase I study to determine the Maximum Tolerated Dose, Recommended Phase 2 Dose, safety, tolerability and Pharmacokinetics of AZD5312.
- Trial name
- NCT02144051
- Testing
- AZD5312
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Prostate Cancer, Pharmacokinetics of Enzalutamide
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
A multiple dose relative bioavailability study in patients with prostate cancer comparing a capsule and a tablet formulation of enzalutamide.
- Trial name
- NCT01902251
- Testing
- Enzalutamide tablet, Enzalutamide capsule
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Astellas Pharma Europe B.V.
Prostate Cancer
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
The primary purpose of this study is to evaluate the efficacy of triptorelin embonate 22.5 mg 6-month formulation administered by the subcutaneous (under the skin) route in: achieving castrate levels of testosterone (< 1.735…
- Trial name
- NCT01656161
- Testing
- Triptorelin embonate 22.5 mg
- Where
- 10 sites in South Africa
- Volunteers
- 120 people
- Sponsor
- Debiopharm International SA
Advanced Solid Cancer, Metastatic Solid Tumor
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors
- Conditions
- Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer
- Trial name
- NCT06666270
- Testing
- SYN818
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Metastatic Castration-resistant Prostate Cancer
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer
The overall objective of this Phase 1 study is to evaluate the safety, PK, and anti-tumor activity of 12 weeks of daily oral dosing with HP518 after selecting the RP2D of HP518 based on assessments of multiple dose escalation in…
- Trial name
- NCT05252364
- Testing
- HP518 - Dose Escalation, HP518 - Dose expansion
- Where
- 5 sites in Australia
- Volunteers
- 22 people
- Sponsor
- Hinova Pharmaceuticals Aus Pty Ltd
Prostate Cancer
Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer
The purpose of this study is to determine whether DCVAC/PCa added after radical primary prostatectomy can improve PSA progression times within 5 years for patients with high risk localized Prostate Cancer.
- Trial name
- NCT02107430
- Testing
- Dendritic Cells DCVAC/PCa, Standard radiotherapy
- Where
- 6 sites in Czechia
- Volunteers
- 62 people
- Sponsor
- SOTIO a.s.
Solid Cancers, BRCA Mutation
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
The primary objective of the study is to evaluate the safety, tolerability, PK, PD, and prilimary efficacy of a PARG inhibitor DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss of function…
- Conditions
- Solid Cancers, BRCA Mutation, HRD Cancer, Breast Cancer
- Trial name
- NCT06614751
- Testing
- DAT-2645 tablet
- Where
- 2 sites in China
- Volunteers
- 112 people
- Sponsor
- Danatlas Pharmaceuticals Co., Ltd
Prostate Cancer
Open Label Trial to Assess Iressa in Prostate Cancer Patients
A study to assess the activity of Iressa in patients who's prostate cancer has recurred, and who have rising PSA levels
- Trial name
- NCT00635856
- Testing
- Gefitinib
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Metastatic Castration-resistant Prostate Cancer
Study With [225Ac]Ac-FL-020 in mCRPC Participants
The purpose of this study is to evaluate the safety, therapeutic effect, and pharmacokinetics of [225Ac]Ac-FL-020 in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- ProTACT (NCT06492122)
- Testing
- [225Ac]Ac-FL-020, Blood samples for PK, [111In]In-FL-020
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 50 people
- Sponsor
- Full-Life Technologies UK Limited
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager acapatamab in subjects with metastatic castration-resistant…
- Trial name
- NCT03792841
- Testing
- acapatamab, Pembrolizumab, Etanercept
- Where
- 30 sites in United States, Australia and 8 more
- Volunteers
- 212 people
- Sponsor
- Amgen
Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
This is a multicenter, open-label, phase II study of YL201 in China to evaluate the efficacy, safety, and PK characteristics of YL201 on mCRPC.
- Trial name
- NCT06241846
- Testing
- YL201 for Injection
- Where
- 24 sites in China
- Volunteers
- 100 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Prostatic Neoplasm, Prostate Cancer
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
The main purpose of this study was to determine whether ADT started before or after sipuleucel-T led to a better immune system response.
- Conditions
- Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma
- Trial name
- NCT01431391
- Testing
- sipuleucel-T, leuprolide acetate
- Where
- 14 sites in United States
- Volunteers
- 68 people
- Sponsor
- Dendreon
Advanced Prostate Cancer
Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT07115446
- Testing
- HS-20093, HRS-5041
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Hansoh BioMedical R&D Company
Prostate Cancer
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
This is a Phase Ib, open-label, multi-centre study to determine the safety, tolerability and pharmacokinetics (PK) of capivasertib when given in combination with novel agents (enzalutamide or abiraterone) to inform the selection…
- Trial name
- NCT04087174
- Testing
- Capivasertib, Enzalutamide, Abiraterone
- Where
- 6 sites in United States, Spain
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer
This is a multi-center, open label, randomized study. Patients will be randomized to one of the following arms with an allocation ratio of 3:1, respectively: Arm A: CP-675,206 + neoadjuvant hormone therapy (NHT) OR Arm B…
- Trial name
- NCT00075192
- Testing
- CP-675,206 and leuprolide acetate and bicalutamide, leuprolide acetate and bicalutamide
- Where
- 11 sites in United States
- Volunteers
- 8 people
- Sponsor
- AstraZeneca
Prostate Cancer
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel (TAK-700) plus prednisone compared with placebo plus prednisone in the treatment of men with progressive, chemotherapy-naive, metastatic…
- Trial name
- NCT01193244
- Testing
- Orteronel, Prednisone
- Where
- 240 sites in United States, Australia and 38 more
- Volunteers
- 1,560 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Cancer
Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of Lutetium Lu 177 JH020002 Injection in adult patients with advanced prostate cancer.
- Trial name
- NCT06139575
- Testing
- Lutetium Lu 177 JH020002 Injection
- Where
- 13 sites in China
- Volunteers
- 90 people
- Sponsor
- Bivision Pharmaceuticals, Inc.
Neuroendocrine Prostate Cancer
A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
- Trial name
- DeLLpro-300 (NCT04702737)
- Testing
- Tarlatamab
- Where
- 21 sites in United States, Australia and 7 more
- Volunteers
- 41 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.